Lehtovirta P, Viinikka L, Ylikorkala O
Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Finland.
Gynecol Oncol. 1990 May;37(2):276-8. doi: 10.1016/0090-8258(90)90347-n.
Serum levels of CA-125 and squamous cell carcinoma-associated antigen (SCC) were measured in 30 patients with squamous cell carcinoma and 12 patients with adenocarcinoma of the uterine cervix. SCC was elevated in 67% of patients with squamous cell carcinoma but in only 25% of patients with adenocarcinoma. In contrast, CA-125 was elevated in 75% of patients with adenocarcinoma but in only 26% of patients with squamous cell carcinoma. These data demonstrate the applicability of the measurement of CA-125 as a tumor marker for cervical adenocarcinoma and confirm the value of the measurement of SCC antigen in patients with cervical squamous cell carcinoma. Moreover, we show that measurement of SCC antigen in adenocarcinoma and measurement of CA-125 in squamous cell carcinoma are of insufficient clinical value.
对30例宫颈鳞状细胞癌患者和12例宫颈腺癌患者测定了血清CA-125和鳞状细胞癌相关抗原(SCC)水平。67%的鳞状细胞癌患者SCC升高,而腺癌患者中只有25%升高。相比之下,75%的腺癌患者CA-125升高,而鳞状细胞癌患者中只有26%升高。这些数据证明了CA-125测定作为宫颈腺癌肿瘤标志物的适用性,并证实了SCC抗原测定对宫颈鳞状细胞癌患者的价值。此外,我们表明腺癌中SCC抗原的测定和鳞状细胞癌中CA-125的测定临床价值不足。